High Chemical Co. et al.; Proposal to Withdraw Approval of 13 New Drug Applications; Opportunity for a Hearing; Withdrawal, 22054 [05-8470]
Download as PDF
<![CDATA[
22054
Federal Register / Vol. 70, No. 81 / Thursday, April 28, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0010]
High Chemical Co. et al.; Proposal to
Withdraw Approval of 13 New Drug
Applications; Opportunity for a
Hearing; Withdrawal
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; withdrawal.
SUMMARY: The Food and Drug
Administration (FDA) is withdrawing a
notice that published in the Federal
Register on January 28, 2005 (70 FR
4134). This notice is being reissued
elsewhere in this issue of the Federal
Register
This notice is withdrawn on
April 28, 2005.
FOR FURTHER INFORMATION CONTACT:
Darlease Hyman, Regulations Policy
Management Staff (HF–26), Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
3480.
DATES:
In the
Federal Register of January 28, 2005 (70
FR 4134), FDA published a notice
announcing an opportunity for a hearing
on the agency’s proposal to withdraw
approval of 13 new drug applications
from multiple sponsors. This notice
published with an inadvertent error.
Therefore, the agency is withdrawing
the notice. Elsewhere in this issue of the
Federal Register, FDA is reissuing the
corrected notice for the convenience of
the reader and to give sponsors the fully
allotted time to respond.
SUPPLEMENTARY INFORMATION:
Dated: April 5, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–8470 Filed 4–27–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0178]
Guidance for Industry and Food and
Drug Administration Staff; Class II
Special Controls Guidance Document:
Dental Bone Grafting Material Devices;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate jul<14>2003
16:00 Apr 27, 2005
Jkt 205001
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Class II Special Controls Guidance
Document: Dental Bone Grafting
Material Devices.’’ This guidance
document describes a means by which
class II dental bone grafting material
devices may comply with the
requirement of special controls.
Elsewhere in this issue of the Federal
Register, FDA is publishing a final rule
to reclassify tricalcium phosphate (TCP)
granules for dental bone repair from
class III (premarket approval) to class II
(special controls), classify into class II
(special controls) other bone grafting
material for dental indications, and
revise the classification name and
identification of the device.
DATES: Submit written or electronic
comments on this guidance at any time.
General comments on agency guidance
documents are welcome at any time.
ADDRESSES: Submit written requests for
single copies on a 3.5″ diskette of the
guidance document entitled ‘‘Class II
Special Controls Guidance Document:
Dental Bone Grafting Material Devices’’
to the Division of Small Manufacturers,
International, and Consumer Assistance
(HFZ–220), Center for Devices and
Radiological Health, Food and Drug
Administration, 1350 Piccard Dr.,
Rockville, MD 20850. Send one selfaddressed adhesive label to assist that
office in processing your request, or fax
your request to 301–443–8818. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance.
Submit written comments concerning
this guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
Identify comments with the docket
number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Michael E. Adjodha, Center for Devices
and Radiological Health (HFZ–480),
Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850,
301–827–5283, e-mail:
michael.adjodha@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 30,
2004 (69 FR 39485), FDA announced the
availability of a draft of this special
controls guidance document and invited
interested persons to comment on it by
September 28, 2004. In addition, in the
same Federal Register (69 FR 39377),
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
FDA proposed to reclassify tricalcium
phosphate (TCP) granules for dental
bone repair from class III to class II
(special controls). Concurrently, FDA
proposed to classify into class II (special
controls) all other bone grafting material
for dental indications, except those that
contained a drug or biologic component;
and to revise the classification name
and identification of the device. In the
proposed rule, FDA identified bone
grafting material as a material such as
hydroxyapatite, tricalcium phosphate,
polylactic acids, or collagen, intended to
fill, augment, or reconstruct periodontal
or bony defects of the oral and
maxillofacial region. FDA received one
comment on the proposed rule and draft
special controls guidance document.
The comment is addressed in the final
rule published elsewhere in this issue of
the Federal Register.
The final rule published elsewhere in
this issue of the Federal Register
reclassifies tricalcium phosphate (TCP)
granules for dental bone repair from
class III (premarket approval) to class II
(special controls) and also classifies
other dental bone grafting materials that
do not contain a drug that is a
therapeutic biologic into class II (special
controls). Bone grafting material devices
that contain a drug that is a therapeutic
biologic will remain in class III and
continue to require premarket approval.
The guidance document provides a
means by which the dental bone grafting
materials in class II may comply with
the requirement of special controls for
class II devices.
Following the effective date of the
final rule, any firm submitting a 510(k)
for the class II devices will need to
address the issues covered in the special
control guidance. However, the firm
need only show that its device meets the
recommendations of the guidance or in
some other way provides equivalent
assurances of safety and effectiveness.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on class II dental bone
grafting material devices. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statute and regulations.
III. Electronic Access
To receive ‘‘Class II Special Controls
Guidance Document: Dental Bone
Grafting Material Devices’’ by fax, call
the CDRH Facts-On-Demand system at
E:\FR\FM\28APN1.SGM
28APN1
]]>Agencies
[Federal Register Volume 70, Number 81 (Thursday, April 28, 2005)]
[Notices]
[Page 22054]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8470]
[[Page 22054]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0010]
High Chemical Co. et al.; Proposal to Withdraw Approval of 13 New
Drug Applications; Opportunity for a Hearing; Withdrawal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing a notice
that published in the Federal Register on January 28, 2005 (70 FR
4134). This notice is being reissued elsewhere in this issue of the
Federal Register
DATES: This notice is withdrawn on April 28, 2005.
FOR FURTHER INFORMATION CONTACT: Darlease Hyman, Regulations Policy
Management Staff (HF-26), Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301-827-3480.
SUPPLEMENTARY INFORMATION: In the Federal Register of January 28, 2005
(70 FR 4134), FDA published a notice announcing an opportunity for a
hearing on the agency's proposal to withdraw approval of 13 new drug
applications from multiple sponsors. This notice published with an
inadvertent error. Therefore, the agency is withdrawing the notice.
Elsewhere in this issue of the Federal Register, FDA is reissuing the
corrected notice for the convenience of the reader and to give sponsors
the fully allotted time to respond.
Dated: April 5, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-8470 Filed 4-27-05; 8:45 am]
BILLING CODE 4160-01-S
